Pierre Fabre

Type: Person

Name: Pierre Fabre

First Reported 11/20/2009 - Updated 11/20/2009 - 1 Documents (in Health)

EU Panel: Affirm Benefits Of Celvapan, Focetria, Pandemrix

LONDON -(Dow Jones)- The European Medicines Agency said Friday it has reviewed further data on the centrally authorized pandemic vaccines, Celvapan, Focetria and Pandemrix and reaffirmed that they have a positive balance of benefits and risks in the context ... [CNN Money - 11/20/2009]

Entities: Focetria, CELVAPAN, docetaxel, Pandemrix

First Reported 11/14/2009 - Updated 11/14/2009 - 1 Documents

Clarins

Cosmetics Packaging Offered in 100% Recycled PET

Every day the world of cosmetics is the theatre of a silent battle. On shop and supermarket shelves, brands vie for consumer preference. In this battle, packaging plays a vital role. That is why Bormioli Rocco, one of the leading manufacturers of plastic ... [Packaging Digest - 11/14/2009]

Entities: Recycling, Yves Rocher, Pierre Fabre, Clarins

First Reported 11/02/2009 - Updated 11/02/2009 - 2 Documents (in Medicine)

ExonHit announces participation in MAPT study

Therapeutic and diagnostic company ExonHit Therapeutics (Paris: ALEHT) said today that, together with Toulouse University Hospital and l'Institut de Recherche Pierre Fabre (IRPF), it will participate in the Multidomain Alzheimer Preventive Trial (MAP ... [M2 - 11/02/2009]

Entities: Alzheimer's Disease, ExonHit Therapeutics SA, Diagnostic, Pierre Fabre

First Reported 11/02/2009 - Updated 11/02/2009 - 1 Documents (in Medicine)

Nearly 80% adolescents in UAE suffer from acne

Medical Symposium urges insurance companies to cover Acne treatmentNearly 80 per cent adolescents in the UAE suffer from acne, which is now considered a disease in medical circles, and some of them resort to wrong treatments based on cosmetics products ... [Eye of Dubai - 11/02/2009]

Entities: United Arab Emirates, Dermatology, Pierre Fabre, dermatologist

First Reported 11/09/2009 - Updated 11/09/2009 - 1 Documents

UPDATE 1-Cypress Bioscience Q3 loss narrower than expected

* Savella launch helps revenue Nov 9 (Reuters) - Cypress Bioscience Inc posted a narrower-than-expected quarterly loss, helped by revenue from fibromyalgia drug Savella. For the third quarter, the company posted a net loss of $5.5 million, or 14 cents ... [Interactive Investor International - 11/09/2009]

Entities: Cypress Bioscience Incorporated, Fibromyalgia, Total Revenue, Pierre Fabre

First Reported 11/10/2009 - Updated 11/10/2009 - 1 Documents

L'Oréal SA

L’Oréal Taps Argentinean Journalist as New Spokeswoman

LOral Paris has selected the prestigious Argentinean television journalist Mara Laura Santilln to be the local face of its Revitalift antiaging product. This is the first time a local personality has been chosen to represent a product in the Dermo-Expertise ... [Global Cosmetic Industry Magazine - 11/10/2009]

Entities: L'Oréal SA, Uruguay, Paris

First Reported 10/17/2009 - Updated 10/17/2009 - 3 Documents (in Health)

Forest Laboratories Inc

Forest Laboratories and Cypress Bioscience Announce Study Shows Patients Treated with Savella...

BusinessWire - Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Savella(R) (milnacipran HCI) 100 mg/day (50 mg twice daily) demonstrated statistically significant and clinically meaningful concurrent ... [Forbes.com - 10/17/2009]

Entities: Fibromyalgia, Cypress Bioscience Incorporated, Forest Laboratories Inc, Placebo

First Reported 06/30/2009 - Updated 06/30/2009 - 2 Documents

Laboratoires Pierre's bladder cancer drug Javlor gets EMEA positive opinion

Laboratoires Pierre Fabre announced that the committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant ... [PharmaBiz - 06/30/2009]

Entities: Bladder Cancer, Pierre Fabre, Metastatic, Laboratoires Pierre Fabre, transitional cell carcinoma

More Content

sort by: Date \| Relevance
EU Panel: Affirm Benefits Of Celvapan, Focetria... [CNN Money - 11/20/2009]
AHA: Patients Suffering STEMI Fare Better with ... [MedPage Today - 11/16/2009]
Cosmetics Packaging Offered in 100% Recycled PET [Packaging Digest - 11/14/2009]
L’Oréal Taps Argentinean Journalist as New... [Global Cosmetic Industry Magazine - 11/10/2009]
UPDATE 1-Cypress Bioscience Q3 loss narrower th... [Interactive Investor International - 11/09/2009]
Blopress [Irish Medical Times - 11/07/2009]
Blopress Plus [Irish Medical Times - 11/07/2009]
Clopidogrel HCS [Irish Medical Times - 11/07/2009]
Instanyl [Irish Medical Times - 11/07/2009]
Nplate [Irish Medical Times - 11/07/2009]
Ondansetron [Irish Medical Times - 11/07/2009]
Profal [Irish Medical Times - 11/07/2009]
Victoza [Irish Medical Times - 11/07/2009]
Denzapine tablets (50mg & 200mg) & Denz... [Irish Medical Times - 11/07/2009]
Monotrim 100mg & 200mg [Irish Medical Times - 11/07/2009]
Salofalk Rectal Foam [Irish Medical Times - 11/07/2009]
Estraderm TTS Discontinued [Irish Medical Times - 11/07/2009]
Trinordiol Discontinued [Irish Medical Times - 11/07/2009]
Xylocaine 4% w/v Topical Mucosal Solution in Sh... [Irish Medical Times - 11/07/2009]
Nearly 80pc UAE adolescents suffer from acne [Trade Arabia - 11/03/2009]
Nearly 80% adolescents in UAE suffer from acne [Eye of Dubai - 11/02/2009]
ExonHit announces participation in MAPT study [M2 - 11/02/2009]
ExonHit Therapeutics to take part in MAPT study... [News-Medical.Net - 11/02/2009]
Nibbles Here and There at Forest Labs [Motley Fool - 10/22/2009]
Forest Laboratories and Cypress Bioscience Anno... [Forbes.com - 10/17/2009]
Forest Laboratories and Cypress Bioscience Anno... [Business Wire via MSN Money - 10/17/2009]
Forest Laboratories and Cypress Bioscience Anno... [Earthtimes.org - 10/17/2009]
Laboratoires Pierre's bladder cancer drug Javlo... [PharmaBiz - 06/30/2009]
Laboratoires Pierre' Javlor Receives Positive O... [Pharmaceutical Business Review - 06/30/2009]
Forest Labs & Cypress Bio postpone launch o... [PharmaBiz - 03/10/2009]

Blogs

sort by: Date \| Relevance
FDA, Clinical Trial Calendar Updates: Actelion,... [Biotech Sector and Stocks Analysis from Seeking ... - 04/21/2009] Mike Havrilla submits:Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars.The FDA ...

Change Password

Log in to Silobreaker

Advanced Search Options

Pierre Fabre